1000097823.jpg
Sol it with reference to apurva shastri microbiology mbbs students.more clinical approach
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Here is a complete, clinically oriented answer paper as per Apurva Shastri Microbiology (MBBS level):
MICROBIOLOGY EXAMINATION - MODEL ANSWERS
(Apurva Shastri Microbiology - Clinical Approach, MBBS)
Q1. 28-year-old man with fever, productive cough, weight loss, hemoptysis × 2 months, not responding to common antibiotics (1+3+3+3 = 10 marks)
a) Provisional Clinical Diagnosis (1 mark)
Pulmonary Tuberculosis (PTB)
Clinical reasoning:
- Young adult male (peak age group for TB)
- Classic triad: fever (evening rise), productive cough, weight loss
- Hemoptysis - highly suggestive of cavitary TB
- Duration: 2 months (chronic course typical of TB)
- Non-response to common antibiotics (TB does not respond to usual broad-spectrum antibiotics like amoxicillin/cephalosporins)
- Rule out: Lung abscess, Bronchiectasis, Carcinoma lung - but non-antibiotic response + young age + 2 months duration points to TB
Causative organism: Mycobacterium tuberculosis - Gram-positive (poorly), acid-fast bacillus (AFB), obligate aerobe, non-spore forming, non-motile
b) Laboratory Diagnosis (3 marks)
Specimen Collection
- Sputum - 3 samples: spot-morning-spot (Revised National TB Control Programme / NTEP protocol)
- Early morning sputum preferred (mucopurulent, > 5 mL)
1. Direct Microscopy (Screening Test)
| Stain | Appearance | Significance |
|---|---|---|
| Ziehl-Neelsen (ZN) stain | Bright red AFB against blue background | Most common, cheap |
| Auramine-Rhodamine (Fluorescence) | Yellow-orange fluorescent bacilli | More sensitive, used for screening large batches |
- CBNAAT (Cartridge-Based Nucleic Acid Amplification Test) / GeneXpert MTB/RIF - First-line test in NTEP India
- Detects MTB DNA AND Rifampicin resistance simultaneously
- Result in ~2 hours
- Sensitivity: 88%, Specificity: 98%
2. Culture (Gold Standard)
| Medium | Characteristics | Time to growth |
|---|---|---|
| Lowenstein-Jensen (L-J) medium | Egg-based, inspissated | 4-8 weeks |
| Middlebrook 7H10/7H11 | Agar-based | 3-4 weeks |
| BACTEC MGIT 960 (liquid) | Fluorometric detection | 1-3 weeks (faster) |
- Colonial morphology on L-J: Rough, raised, warty/cauliflower-like colonies ("eugonic", buff-colored) - "bread crumb" or "Ruff colonies"
3. Sensitivity Testing
- Rapid: Line Probe Assay (LPA) - detects MDR-TB
- Drug Susceptibility Testing (DST) on culture
4. Immunological Tests
- Tuberculin Test (Mantoux): 0.1 mL of 5 TU PPD intradermal on forearm volar aspect. Read at 48-72 hours. Induration ≥10 mm = positive (in normal adults in India)
- IGRA (Interferon Gamma Release Assay): QuantiFERON-TB Gold - measures IFN-γ release to MTB-specific antigens (ESAT-6, CFP-10); not affected by BCG vaccination
5. Imaging
- Chest X-ray: Upper lobe infiltrates, cavitation, fibrosis - highly suggestive
6. Molecular/Others
- LAMP (Loop-mediated isothermal amplification)
- Adenosine Deaminase (ADA) in pleural fluid if pleural effusion present
c) Management (3 marks)
NTEP (National TB Elimination Programme) - Nikshay Portal Registration Mandatory
Category I (New case):
| Phase | Duration | Drugs | Doses |
|---|---|---|---|
| Intensive Phase | 2 months | HRZE (Isoniazid + Rifampicin + Pyrazinamide + Ethambutol) | Daily |
| Continuation Phase | 4 months | HR (Isoniazid + Rifampicin) | Daily |
Drug doses (weight-based):
- H (Isoniazid): 5 mg/kg/day
- R (Rifampicin): 10 mg/kg/day
- Z (Pyrazinamide): 25 mg/kg/day
- E (Ethambutol): 15 mg/kg/day
Important add-ons:
- Pyridoxine (Vit B6): 10 mg/day with Isoniazid (prevents peripheral neuropathy)
- Test HIV status (TB-HIV co-management)
- Nikshay Poshan Yojana: ₹500/month nutritional support
If MDR-TB (Rifampicin resistance on GeneXpert):
- Bedaquiline-based regimen (BPaL or BPaLM)
- Refer to MDR-TB centre
Monitoring:
- Sputum smear at end of 2 months (intensive phase)
- LFTs at baseline (rifampicin, pyrazinamide are hepatotoxic)
- Visual acuity (ethambutol - optic neuritis)
d) Prophylaxis and Vaccination Schedule (3 marks)
1. BCG Vaccination (Primary Prevention)
- Vaccine: BCG (Bacille Calmette-Guerin) - Live attenuated strain of M. bovis
- Schedule (India - NIP):
- Given at birth or as early as possible (< 1 year)
- Single dose: 0.1 mL intradermal, left deltoid
- < 1 month: 0.05 mL
- Efficacy: Protects against severe forms (miliary TB, TB meningitis) in children - 60-80% efficacy; less protection against pulmonary TB in adults
- Contraindication: Immunocompromised patients (HIV, malignancy), active TB
2. Chemoprophylaxis
| Population | Drug | Duration |
|---|---|---|
| Contacts of active TB (TST/IGRA positive, no disease) | Isoniazid (INH) | 6 months |
| HIV + latent TB (LTBI) | Isoniazid Preventive Therapy (IPT) | 6 months (or 36 months) |
| Children < 5 years, household contact | INH 10 mg/kg/day | 6 months |
3. Other Preventive Measures
- Early diagnosis and treatment of active cases (prevent transmission)
- DOTS (Directly Observed Treatment, Short-course) - ensures compliance
- Adequate ventilation, sunlight (UV kills bacilli)
- Notification to health authorities (TB is notifiable disease in India since 2012)
- Nutritional support, treatment of HIV co-infection
Q2. Short Notes (5×4 = 20 marks)
(a) Cryptococcus neoformans
Classification: Encapsulated yeast, Basidiomycetes; two species: C. neoformans (serotype A/D) and C. gattii (serotype B/C)
Morphology:
- Spherical yeast, 4-20 μm
- Thick polysaccharide capsule (hallmark) - visualized by India Ink preparation (clear halo = capsule against black background)
- Reproduces by narrow-based budding
Source/Epidemiology:
- C. neoformans: Pigeon droppings (high urea environment)
- C. gattii: Eucalyptus trees (endemic)
- Route: Inhalation of spores (basidiospores)
Virulence Factors (Apurva Shastri highlights):
- Thick polysaccharide capsule - inhibits phagocytosis, anti-inflammatory
- Melanin production (phenoloxidase enzyme) - free radical scavenging, neurotropism
- Growth at 37°C
- Urease production
- Alpha-mating phenotype (MATα)
Clinical Disease:
| Disease | Features |
|---|---|
| Cryptococcal meningitis | Most common; subacute, headache, fever, neck stiffness; mainly in HIV (CD4 < 100) |
| Pulmonary cryptococcosis | Cough, fever; often subclinical in immunocompetent |
| Cutaneous | Papules, nodules, molluscum-like |
Diagnosis:
- CSF India Ink preparation - capsule visualization
- Latex Agglutination Test (LAT) - detects capsular polysaccharide antigen in CSF/serum (sensitive + specific)
- Culture: Sabouraud's Dextrose Agar - white mucoid colonies
- Birdseed agar (Niger seed agar): Brown/dark colonies (melanin production)
Treatment:
- Induction: Amphotericin B + Flucytosine × 2 weeks
- Consolidation: Fluconazole × 8 weeks
- Maintenance: Fluconazole lifelong (in HIV)
(Reference: Medical Microbiology 9e, p.655)
(b) Mycotoxins
Definition: Toxic secondary metabolites produced by fungi (molds), especially in contaminated food/feed.
Clinically Important Mycotoxins:
| Mycotoxin | Fungus | Food Affected | Disease |
|---|---|---|---|
| Aflatoxin (B1, B2, G1, G2) | Aspergillus flavus, A. parasiticus | Peanuts, maize, cereals | Acute hepatitis (high dose), Hepatocellular carcinoma (chronic - synergistic with HBV), Aflatoxicosis |
| Ochratoxin A | Aspergillus ochraceus, Penicillium | Cereals, coffee | Nephrotoxicity, immunosuppression |
| Trichothecenes (e.g., Deoxynivalenol/DON, Vomitoxin) | Fusarium spp. | Wheat, corn | GI illness, Alimentary Toxic Aleukia (ATA) |
| Zearalenone | Fusarium spp. | Corn | Estrogenic effects, reproductive disorders |
| Fumonisin B1 | Fusarium moniliforme | Corn | Esophageal cancer, equine leucoencephalomalacia |
| Ergot alkaloids | Claviceps purpurea | Rye (ergotism) | St. Anthony's Fire - vasoconstriction, gangrene, hallucinations |
| Patulin | Penicillium expansum | Apple juice | GI irritant |
Aflatoxin (Most important clinically):
- Heat stable - not destroyed by cooking
- Aflatoxin B1 is the most potent naturally occurring hepatocarcinogen
- Converted to epoxide by cytochrome P450 - binds DNA → mutation in p53 codon 249
Prevention: Proper storage, reduce moisture content (< 13%), avoid contaminated food, food safety regulations
(c) Opportunistic Fungal Infections
Definition: Fungal infections occurring in immunocompromised hosts (HIV/AIDS, transplant recipients, cancer patients on chemotherapy, ICU patients on broad-spectrum antibiotics/corticosteroids, diabetics).
Common Opportunistic Fungi and their Clinical Significance:
| Organism | Risk Group | Disease | Key Feature |
|---|---|---|---|
| Candida albicans | HIV (CD4 < 200), antibiotics, catheters | Oral thrush, esophagitis, invasive candidiasis, candidemia | Germ tube positive, pseudohyphae |
| Aspergillus fumigatus | Neutropenia, transplant, steroids | Invasive pulmonary aspergillosis, sinusitis | Septate hyphae, 45° branching; Galactomannan antigen |
| Cryptococcus neoformans | HIV (CD4 < 100) | Meningitis | India ink, capsule |
| Pneumocystis jirovecii | HIV (CD4 < 200), immunosuppressed | PCP pneumonia (Pneumocystis pneumonia) | GMS stain (cysts), trophozoites; Methenamine silver |
| Mucor/Rhizopus | Diabetics (especially ketoacidosis), immunocompromised | Mucormycosis - rhinocerebral, pulmonary, GI | Broad, non-septate hyphae, 90° branching; angioinvasive |
| Histoplasma capsulatum | Cave workers/miners (bat/bird droppings) | Histoplasmosis - Darling's disease | Intracellular yeast in macrophages |
Diagnosis: Culture on SDA, histopathology with PAS/GMS staining, serum galactomannan (Aspergillus), beta-D-glucan (all except Cryptococcus and Mucor), CT chest (Halo sign in aspergillosis), PCR
Treatment: Depends on organism - Azoles (fluconazole, voriconazole, posaconazole), Amphotericin B (polyene), Echinocandins (caspofungin, micafungin)
Prevention: Antifungal prophylaxis in high-risk patients (fluconazole for Candida; posaconazole for Aspergillus in neutropenic patients)
(d) Darling's Disease (Histoplasmosis)
Causative Agent: Histoplasma capsulatum (misnomer - no true capsule; the "capsule" is a shrunken cell wall artifact)
Classification: Dimorphic fungus
- In soil (25°C): Mold form with tuberculate macroconidia (hallmark)
- In tissue (37°C): Small, oval yeast (2-4 μm) - intracellular within macrophages
Epidemiology:
- Endemic in Ohio and Mississippi River valleys (USA)
- Source: Soil contaminated with bat and bird (starling) droppings (high nitrogen content)
- Occupation: Cave explorers (spelunkers), bat cave workers, demolition workers
Pathogenesis:
- Inhalation of microconidia
- Macroconidia → yeast phase in alveolar macrophages
- Granuloma formation (similar to TB - hence "Poor man's TB")
- Cell-mediated immunity controls infection in immunocompetent
- Dissemination in HIV/immunocompromised
Clinical Forms:
| Form | Features |
|---|---|
| Asymptomatic | 95% of infections (immunocompetent) |
| Acute pulmonary | Self-limiting flu-like illness |
| Chronic pulmonary | Mimics TB - cavitation, upper lobe |
| Progressive Disseminated | HIV, elderly - hepatosplenomegaly, adrenal involvement, oral ulcers |
| Mediastinal | Mediastinal fibrosis |
Diagnosis:
- Microscopy: Giemsa/Wright stain of bone marrow/blood - small oval yeast INSIDE macrophages (classic)
- Culture (Gold standard): SDA at 25°C - mold with wheel-spoke or tuberculate macroconidia
- Urine/Serum Antigen EIA: Most sensitive for disseminated (immunocompromised)
- Complement Fixation Test (CFT): Serology
- Histopathology: GMS (Gomori Methenamine Silver) or PAS stain
Treatment:
- Mild: Itraconazole 200 mg TDS × 3 days then BD × 3 months
- Severe/Disseminated: Amphotericin B (liposomal) → step-down to Itraconazole
Q3. Differences (5×2 = 10 marks)
A) Amoebic Dysentery vs Bacillary Dysentery
| Feature | Amoebic Dysentery | Bacillary Dysentery |
|---|---|---|
| Causative organism | Entamoeba histolytica (Protozoan) | Shigella spp. (Bacterium - S. dysenteriae, S. flexneri, S. sonnei, S. boydii) |
| Onset | Gradual (subacute) | Acute/abrupt |
| Stool appearance | "Anchovy sauce" - blood-stained, foul smelling, scanty mucus; blood and pus separate | Mucus, blood, pus intimately mixed; "Rectal cast"; watery initially then bloody |
| Tenesmus | Mild | Severe |
| Fever | Low grade/absent | High fever (>38.5°C) |
| Abdominal pain | Right iliac fossa, colicky | Left iliac fossa, colicky (sigmoid pain) |
| WBC in stool | Few, degenerated (lysed by amoeba) | Numerous pus cells (WBCs) |
| RBC in stool | Clumped (amoeba eats RBCs - "erythrophagocytosis") | Scattered |
| Extraintestinal complications | Amoebic liver abscess (most common), brain, lung abscess | HUS (Shiga toxin - S. dysenteriae type 1), TTP, Reiter's syndrome |
| Sigmoidoscopy | Flask-shaped (bottle-neck) ulcers with overhanging edges, normal intervening mucosa | Diffuse mucosal hyperemia, superficial ulcers |
| Diagnosis | Stool microscopy - quadrinucleate cyst/trophozoite with ingested RBCs; stool antigen (ELISA) | Stool culture on MacConkey/XLD agar - non-lactose fermenter |
| Treatment | Metronidazole + Diloxanide furoate (for luminal cysts) | Fluoroquinolones (Ciprofloxacin), Azithromycin; Supportive care |
B) Live (OPV) vs Killed (IPV) Vaccines of Polio
| Feature | OPV (Oral Polio Vaccine / Sabin) | IPV (Inactivated Polio Vaccine / Salk) |
|---|---|---|
| Type | Live attenuated | Killed (inactivated by formalin) |
| Route | Oral (2 drops) | Intramuscular injection |
| Strains | All 3 serotypes (1, 2, 3) - in bOPV: only 1 & 3 (after type 2 eradication) | All 3 serotypes |
| Immunity induced | Humoral (IgG) + Secretory IgA (mucosal) + Cell-mediated | Humoral (IgG) only - NO mucosal immunity |
| Herd immunity | Yes - vaccine virus spreads to contacts | No |
| VAPP (Vaccine-Associated Paralytic Poliomyelitis) | 1 in 2.4 million doses (risk) | None |
| Cold chain | Required (sensitive to heat) | Less sensitive |
| Cost | Cheap | Expensive |
| Use in India (current) | bOPV (types 1+3) at birth, 6, 10, 14 weeks + pulse polio; IPV added at 6 & 14 weeks | Given at 6 and 14 weeks (fractional IPV - fIPV intradermally) |
| Contraindication | Immunocompromised patients (risk of VAPP) | Safe even in immunocompromised |
C) Lepromatous vs Tuberculoid Leprosy
| Feature | Lepromatous Leprosy (LL) | Tuberculoid Leprosy (TL) |
|---|---|---|
| Immunity | Poor CMI (T-cell anergy); high humoral | Strong CMI; low humoral |
| Bacillary load | Very high (multibacillary - MB) - >5 patches | Low (paucibacillary - PB) |
| Skin lesions | Numerous, diffuse, symmetric; poorly defined; HYPOPIGMENTED + ERYTHEMATOUS | Few (1-5), well-defined, HYPOPIGMENTED with raised erythematous edges |
| Sensation | Preserved (early)/mildly impaired | Severely impaired/absent (anesthetic) |
| Nerve involvement | Diffuse, symmetric (glove and stocking neuropathy) | Single/few nerve trunks - asymmetric, thickened nerves |
| Lepromin test | Negative (poor CMI) | Positive |
| Histopathology | "Lepra cells" (Virchow cells) - foamy macrophages loaded with bacilli; "Globi"; no granuloma | Well-formed epithelioid cell granulomas; Langhans giant cells; few/no bacilli |
| AFB in slit skin smear | Numerous (BI: 4+ to 6+) | None/rare (BI: 0 to 1+) |
| Complications | Saddle nose deformity, madarosis (loss of eyebrows), leonine facies, orchitis, gynecomastia | Claw hand, foot drop, wrist drop, lagophthalmos |
| Treatment | MDT: Rifampicin + Dapsone + Clofazimine × 12 months | MDT: Rifampicin + Dapsone × 6 months |
D) IgG vs IgM Antibodies
| Feature | IgG | IgM |
|---|---|---|
| Structure | Monomer | Pentamer (10 antigen-binding sites) |
| Molecular weight | 150 kDa | 900 kDa |
| % of total Ig | 75-80% (most abundant) | 5-10% |
| Response | Secondary (anamnestic) immune response | Primary immune response (first to appear) |
| Affinity maturation | High affinity | Low affinity (but high avidity due to pentameric structure) |
| Half-life | 23 days (longest) | 5 days |
| Placental transfer | Yes (only Ig to cross placenta - provides neonatal immunity) | No |
| Complement activation | Via classical pathway (less efficient - 2 IgG molecules needed) | Via classical pathway (MOST efficient - 1 pentameric molecule) |
| Opsonization | Yes (major opsonin) | Less efficient |
| Clinical use | Detection = past infection/immunity; Passive immunization | Detection = acute/recent infection; ABO blood group antibodies are IgM |
| Examples | Anti-tetanus, anti-rubella IgG = immunity | Rheumatoid factor (IgM anti-IgG); Cold agglutinins; Widal test (anti-O = IgM) |
E) Type II vs Type III Hypersensitivity Reactions
| Feature | Type II (Cytotoxic) | Type III (Immune Complex) |
|---|---|---|
| Mechanism | Antibody (IgG/IgM) binds to cell surface antigens → complement activation, ADCC, phagocytosis | Soluble antigen-antibody immune complexes deposited in tissues → complement activation → inflammation |
| Antibody | IgG, IgM (cell-bound) | IgG (soluble complexes) |
| Antigen location | Cell surface (endogenous or exogenous attached to cell) | Soluble (circulating) |
| Complement | Activated (lysis, opsonization) | Activated (C3a, C5a - chemotaxis, anaphylatoxins) |
| Cells involved | Complement, NK cells, phagocytes | Neutrophils (attracted by C5a) - releasing lysosomal enzymes |
| Onset | Minutes to hours | 6-8 hours (Arthus) to days (serum sickness) |
| Examples | - Autoimmune hemolytic anemia - Myasthenia gravis (anti-AChR) - Graves' disease (anti-TSH-R) - Goodpasture syndrome - ABO incompatibility transfusion reaction - Pemphigus | - Serum sickness (anti-horse serum) - Systemic Lupus Erythematosus (SLE) - Post-streptococcal glomerulonephritis - Arthus reaction - Hypersensitivity pneumonitis (Farmer's lung) - Polyarteritis nodosa |
| Coombs test | Direct Coombs positive (in hemolytic anemia) | Negative |
| Target organ | Specific cells/tissues | Blood vessels, kidneys, joints, skin (wherever complexes deposit) |
Q4. Explain Briefly (5×4 = 20 marks)
(a) Ante Mortem Diagnosis of Rabies
Ante mortem = Diagnosis in a LIVING patient (as opposed to post mortem diagnosis)
Rabies is caused by Rabies lyssavirus (Rhabdoviridae, bullet-shaped, ss-RNA, negative-sense)
Specimens: Must collect MULTIPLE specimens simultaneously
| Specimen | Test | Finding |
|---|---|---|
| Saliva / Throat swab | RT-PCR (most sensitive for ante mortem) | Detects viral RNA |
| CSF | RT-PCR | Viral RNA |
| Nape of neck skin biopsy (with hair follicles - rich in nerve endings) | Direct Fluorescent Antibody (DFA) test | Viral antigen in nerve fibers around hair follicles |
| Nuchal skin biopsy | RT-PCR | Viral RNA |
| Serum | RFFIT (Rapid Fluorescent Focus Inhibition Test) - virus neutralizing antibodies | Antibody titer (not reliable in unvaccinated - may appear late) |
| Urine | RT-PCR | Viral RNA (less reliable) |
| Corneal impression smear | DFA (less used now) | Viral antigen in corneal epithelium |
Key Points:
- Negri bodies (pathognomonic eosinophilic cytoplasmic inclusions) found in neurons (especially Purkinje cells of cerebellum, hippocampal neurons) - seen on POST-MORTEM, NOT ante mortem
- Negri bodies stained with Seller's stain (magenta bodies in blue background)
- RT-PCR is the gold standard for ante mortem diagnosis
- Serology useful only in vaccinated individuals or late-stage disease
- Clinical diagnosis remains important: Hydrophobia, aerophobia, agitation, ascending paralysis (dumb rabies)
Ante mortem vs Post mortem:
- Ante mortem: RT-PCR (saliva, CSF, urine), DFA (skin biopsy), serology
- Post mortem: Negri bodies in brain tissue (hippocampus/cerebellum), DFA on brain tissue
(b) Bacteriophages
Definition: Viruses that infect bacteria ("phage" = to eat). Discovered by Twort (1915) and d'Herelle (1917).
Structure:
- Head (icosahedral) - contains dsDNA or ssRNA genome
- Tail - tail fibers (host recognition), base plate, tail pins
- Largest: T4 phage (E. coli)
Classification:
| Type | Description |
|---|---|
| Virulent/Lytic phage | Obligate lytic cycle - lyse the host bacterium |
| Temperate/Lysogenic phage | Can integrate into bacterial chromosome as prophage; may enter lytic cycle later |
Lytic Cycle: Adsorption → Penetration → Biosynthesis (replication) → Maturation → Lysis → Release
Lysogenic Cycle: Phage DNA integrates into bacterial chromosome → lysogeny → Prophage replicated with bacterial DNA → induced by UV/chemicals → enters lytic cycle
Medical Importance of Bacteriophages:
| Importance | Example |
|---|---|
| Lysogenic conversion (phage-encoded toxins/virulence factors) | C. diphtheriae + β-phage → Diphtheria toxin; V. cholerae + CTX-phage → Cholera toxin; S. pyogenes + phage → Erythrogenic toxin; C. botulinum + phage → Botulinum toxin (some strains) |
| Phage typing (epidemiology) | Typing of S. aureus, Salmonella typhi - used to trace outbreak sources |
| Transduction | Mechanism of gene transfer between bacteria (generalized and specialized) - spread of antibiotic resistance |
| Phage therapy | Therapeutic use against antibiotic-resistant bacteria (MDR organisms) |
| Molecular biology tools | Lambda phage cloning vectors, phage display |
One-liner: Bacteriophages are clinically relevant because lysogenic conversion by temperate phages confers virulence (toxin production) to otherwise harmless bacteria.
(c) HEV (Hepatitis E Virus)
Classification: Hepeviridae family, Genus Hepevirus; ss-RNA, positive-sense, non-enveloped, icosahedral, 27-34 nm
Genotypes:
- Genotype 1 & 2: Humans only; epidemic/endemic in developing countries (India, Southeast Asia, Africa)
- Genotype 3 & 4: Zoonotic (pigs, deer) - found in developed countries; chronic HEV in immunocompromised
Transmission:
- Feco-oral route (like HAV) - contaminated water (most common)
- Waterborne outbreaks (hallmark of HEV - "large waterborne outbreaks")
- Zoonotic: undercooked pork/deer (GT 3, 4)
Clinical Features:
| Feature | Details |
|---|---|
| Incubation | 2-9 weeks |
| Presentation | Acute icteric hepatitis; prodrome of fever, malaise, anorexia |
| Course | Self-limiting in immunocompetent |
| Special group | Pregnant women - Mortality 20-25% (esp. 3rd trimester) - due to fulminant hepatic failure; unique to HEV (not seen with HAV) |
| Chronic HEV | Genotype 3 in immunocompromised (transplant patients) → progressive liver fibrosis |
Diagnosis:
- Anti-HEV IgM: Acute infection
- Anti-HEV IgG: Past infection/immunity
- RT-PCR: Confirmatory; useful in immunocompromised (poor antibody response)
- HEV RNA in stool (early phase)
Diagnosis distinction from HAV: HEV = large waterborne outbreaks + danger in pregnancy; HAV = common in children, no maternal mortality
Treatment:
- Supportive (self-limiting)
- Ribavirin (for chronic HEV in immunocompromised)
- Reduce immunosuppression in transplant recipients
Vaccine:
- Hecolin (rHEV vaccine) - approved in China; recombinant HEV239 vaccine; NOT yet globally available
- No licensed vaccine in India currently
Prevention: Safe drinking water, sanitation, hygiene. HEV spreads during floods (India - endemic for GT1).
(d) Oncogenic Viruses and Oncogenes
Oncogenic Viruses (Tumor Viruses)
Definition: Viruses capable of transforming normal cells into malignant cells.
Mechanisms of Oncogenesis:
- Insertional mutagenesis - viral DNA integrates near proto-oncogene → activation
- Transduction of oncogenes - viral oncogenes (v-onc) encode mutant growth factors/kinases
- Trans-activation - viral proteins activate cellular oncogenes
- Inactivation of tumor suppressor genes (p53, Rb) by viral proteins
Important Oncogenic Viruses:
| Virus | Associated Cancer | Mechanism |
|---|---|---|
| HPV (Human Papillomavirus) types 16, 18 | Cervical carcinoma (most common), Oropharyngeal, anal, penile | E6 → degrades p53; E7 → inactivates Rb |
| HBV + HCV | Hepatocellular Carcinoma (HCC) | Chronic inflammation → cirrhosis → HCC; HBx protein |
| EBV (Epstein-Barr Virus) | Burkitt's lymphoma (t[8;14] - c-myc); Nasopharyngeal carcinoma; Hodgkin's lymphoma; PTLD (post-transplant) | LMP-1 (mimics CD40), EBNA-2 |
| HTLV-1 (Human T-cell Lymphotropic Virus type 1) | Adult T-cell leukemia/lymphoma (ATL); Tropical spastic paraparesis | Tax protein → activates IL-2, IL-2R → T-cell proliferation |
| HHV-8 (KSHV) | Kaposi's sarcoma; Primary effusion lymphoma; Multicentric Castleman's disease | vIL-6, vCyclins, FLICE inhibitory protein |
| MCPyV (Merkel Cell Polyomavirus) | Merkel cell carcinoma | T antigen inactivates Rb |
| H. pylori (bacterium, not virus) | MALT lymphoma, gastric carcinoma | CagA protein - included in tumor microbiology |
Oncogenes
Definition: Genes that when mutated/overexpressed, promote uncontrolled cell proliferation (derived from proto-oncogenes - normal genes regulating cell growth).
Proto-oncogene → Oncogene by: point mutation, amplification, chromosomal translocation, insertional mutagenesis
Categories of Oncogene Products:
| Category | Oncogene | Cancer |
|---|---|---|
| Growth factors | sis (PDGF-β chain) | Glioblastoma |
| Growth factor receptors (RTKs) | erb-B2/HER2/neu | Breast cancer (trastuzumab target) |
| Signal transducers (GTPases) | ras (K-ras, H-ras, N-ras) | Colon, lung, pancreatic cancer |
| Non-receptor tyrosine kinases | abl → BCR-ABL (t[9;22] Philadelphia chromosome) | CML |
| Transcription factors | myc (c-myc) | Burkitt's lymphoma; N-myc in neuroblastoma |
| Anti-apoptotic proteins | bcl-2 (t[14;18]) | Follicular lymphoma |
Tumor Suppressor Genes (Anti-oncogenes):
- p53 ("guardian of the genome") - mutated in >50% of all cancers
- Rb (retinoblastoma gene) - mutated in retinoblastoma, osteosarcoma
- APC - colon cancer
- BRCA1/BRCA2 - breast/ovarian cancer
Q5. Explain Briefly (5×4 = 20 marks)
A) Role of Clinical Microbiologist in Interprofessional Collaboration for ICU Management
Role of Clinical Microbiologist in ICU:
A clinical microbiologist functions as a critical consultant member of the ICU team.
| Role | Details |
|---|---|
| Antibiotic stewardship | Review culture reports, advise on appropriate antimicrobial selection, de-escalation (broad to narrow spectrum), prevent emergence of MDR organisms |
| Infection control / HAI prevention | Hospital-acquired infections (HAIs): VAP, CLABSI, CAUTI, SSI - monitors organisms, identifies clusters/outbreaks |
| Laboratory guidance | Advise on what samples to collect, when to collect (before antibiotics), proper collection technique to avoid contamination |
| Interpretation of cultures | Differentiate between colonization vs true infection (e.g., MRSA in sputum - colonizer or pathogen?) |
| MDR organism management | Advise on treatment of MRSA, VRSA, ESBL/CRE Klebsiella, Acinetobacter, Pseudomonas |
| Outbreak investigation | Identify point source (e.g., contaminated ventilator circuits, IV fluids) using molecular typing |
| Biofilm-related infections | Catheter-related bloodstream infections (CRBSIs) - advise on catheter removal vs lock therapy |
| Infection committee | Member of hospital infection control committee (HICC) |
| Education | Train ICU nursing and medical staff on hand hygiene (WHO 5 moments), PPE usage, sterile technique |
| Rapid diagnostics | Liaise for MALDI-TOF, CBNAAT, multiplex PCR for rapid pathogen identification |
Key organisms of concern in ICU: ESKAPE pathogens - Enterococcus faecium, S. aureus, K. pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.
B) Management of Needle Stick Injury (NSI)
Definition: Accidental puncture of skin by a needle or sharp instrument contaminated with blood/body fluids.
Pathogens of concern: HIV, HBV, HCV (transmission risk in order: HBV > HCV > HIV)
Immediate Management (First Aid) - Do within seconds:
- Do NOT suck/squeeze the wound
- Wash immediately with soap and water for 10-15 minutes
- Allow to bleed freely
- Apply antiseptic (povidone iodine, 70% alcohol)
- Do NOT apply tourniquet
Assessment:
- Source patient status: HIV, HBsAg, Anti-HCV
- Exposed healthcare worker (HCW): Baseline HIV, HBsAg, anti-HBs, anti-HCV
- Nature of injury: Depth, hollow needle vs solid, gloves worn, volume of blood
Post-Exposure Prophylaxis (PEP):
| Pathogen | PEP | When to start |
|---|---|---|
| HIV | Tenofovir + Lamivudine + Dolutegravir (TDF+3TC+DTG) - preferred; or TDF+FTC+LPV/r | Within 2 hours (max 72 hours); 28-day course |
| HBV | HBV vaccine (if unvaccinated) + HBIG (Hepatitis B Immune Globulin) 0.06 mL/kg IM | Within 24 hours |
| HCV | No proven PEP; monitor HCV RNA at 4-6 weeks; if positive → treat with DAAs | - |
Documentation:
- Register in NSI register (Nikshay/hospital register)
- Report to occupational health/infection control officer
- Incident report form
Follow-up Testing:
- HIV at 6 weeks, 3 months, 6 months (if negative - cleared)
- LFTs for HBV/HCV monitoring
Prevention:
- Safe needle devices (retractable, needleless systems)
- No recapping of needles
- Proper disposal in puncture-proof containers (sharp boxes/white-translucent bins)
- Universal precautions/Standard precautions
C) Biomedical Waste Management
Legal Framework: Biomedical Waste Management Rules, 2016 (amended 2019) - Government of India, under Environment Protection Act 1986
Definition: Waste generated during diagnosis, treatment, immunization of humans/animals, or research thereof.
Classification and Color-Coding (BMW Rules 2016):
| Colour | Bag/Container | Waste Category | Treatment |
|---|---|---|---|
| Yellow | Plastic bag | Human anatomical waste, chemical waste, discarded medicines, microbiological waste, blood bags | Incineration or Deep burial |
| Red | Plastic bag | Contaminated recyclable waste (IV sets, syringes without needles, bottles) | Autoclaving → shredding → recycling |
| White (translucent) | Puncture-proof container | Sharps (needles, blades, broken glass with blood) | Autoclaving/Dry heat → shredding → secured landfill |
| Blue | Puncture-proof box/cardboard | Broken/discarded glassware, metallic implants | Autoclaving + shredding OR secure landfill |
Treatment Technologies:
- Incineration - high-temperature combustion (≥800°C); reduces volume by 90%; flue gas scrubbing needed
- Autoclaving - steam sterilization at 121°C, 15 psi, 30 min; for microbiological waste
- Chemical disinfection - 1% hypochlorite for liquid waste (body fluids)
- Secure landfill - treated solid waste
- Deep burial - anatomical waste in remote areas (only if no incinerator available)
Key Points for MBBS/Clinical:
- All HCWs must wear PPE while handling BMW
- Waste must NOT be mixed
- BMW must be transported in covered vehicles to Common Biomedical Waste Treatment Facility (CBWTF) within 48 hours
- Hospitals must register with State Pollution Control Board (SPCB)
- No burning of BMW in open areas
D) Neurocysticercosis
Causative Agent: Larval stage (Cysticercus cellulosae) of Taenia solium (pork tapeworm)
Pathogenesis:
- Normal cycle: Humans ingest raw/undercooked pork → intestinal tapeworm (taeniasis)
- Accidental cysticercosis: Humans ingest T. solium eggs (feco-oral) → Oncospheres released → penetrate intestinal wall → blood → brain, muscle, eye, skin
- In brain: larvae form cysts → surrounded by host granulomatous reaction → calcification
Clinical Features:
- Epilepsy/Seizures - MOST COMMON presentation (new-onset seizures in young adults from endemic area = NCC until proven otherwise)
- Headache, raised intracranial pressure
- Focal neurological deficits
- Hydrocephalus (ventricular cysts)
- Meningitis (subarachnoid cysts - racemose form)
- Visual disturbances (ocular NCC)
Diagnosis:
| Test | Finding |
|---|---|
| CT Brain (preferred) | Multiple hypodense cysts with scolex ("hole-with-dot" sign); ring-enhancing lesion; calcifications |
| MRI Brain | Better for posterior fossa, ventricular cysts; scolex visible |
| ELISA (serum/CSF) | Anti-cysticercal antibodies (ELISA) |
| CSF analysis | Lymphocytic pleocytosis, elevated protein, low glucose (if meningeal involvement) |
| Stool exam | T. solium eggs/proglottids (if concurrent taeniasis) |
Treatment:
| Drug | Dose | Note |
|---|---|---|
| Albendazole (preferred) | 15 mg/kg/day × 8-30 days | Better CNS penetration; 400 mg BD |
| Praziquantel | 50-100 mg/kg/day in 3 divided doses | Alternative |
| Dexamethasone | Along with anthelminthic | Reduces inflammation from dying cysts |
| Anti-epileptics | Phenytoin/Levetiracetam | Control seizures |
| Surgery/VP shunt | For obstructive hydrocephalus, ventricular cysts |
Prevention:
- Avoid open defecation (eggs in human feces)
- Cook pork thoroughly (internal temp > 63°C kills larvae)
- Handwashing before food
- Inspect pork at abattoir - "measly pork" = cysticerci visible in muscle
- Sanitary disposal of human feces
(Reference: The Washington Manual of Medical Therapeutics; Bradley and Daroff's Neurology in Clinical Practice)
Summary Table - Quick Recall
| Q | Topic | Key One-liner |
|---|---|---|
| Q1 | TB | GeneXpert first-line + NTEP 2HRZE/4HR regimen + BCG at birth |
| Q2a | Cryptococcus | India ink capsule + Latex agglutination in HIV meningitis |
| Q2b | Mycotoxins | Aflatoxin B1 = hepatocarcinogen from A. flavus in peanuts |
| Q2c | Opportunistic fungi | ABCPM - Aspergillus, Candida, Cryptococcus, Mucor, PCP |
| Q2d | Darling's disease | Intracellular yeast in macrophages, tuberculate macroconidia |
| Q3A | Dysentery | Amoebic = anchovy sauce, liver abscess; Bacillary = pus cells, HUS |
| Q3B | Polio vaccine | OPV = mucosal immunity + herd immunity; IPV = no VAPP |
| Q3C | Leprosy | Lepromatous = negative lepromin, Virchow cells; Tuberculoid = anesthetic patches |
| Q3D | IgG vs IgM | IgM = first/primary/pentamer; IgG = secondary/crosses placenta |
| Q3E | Hypersensitivity | Type II = cell-bound antigen; Type III = immune complexes |
| Q4a | Rabies | RT-PCR saliva/CSF = antemortem gold standard; Negri bodies = postmortem |
| Q4b | Bacteriophages | Lysogenic conversion → diphtheria/cholera toxin |
| Q4c | HEV | Waterborne outbreaks + maternal mortality in 3rd trimester |
| Q4d | Oncogenic viruses | HPV16/18 (E6 p53, E7 Rb) → cervical cancer; EBV → Burkitt's |
| Q5A | Microbiologist ICU | Stewardship + HAI control + MDR management + outbreak investigation |
| Q5B | NSI | Wash + PEP-HIV within 2 hours (TDF+3TC+DTG × 28 days) + HBIG for HBV |
| Q5C | BMW | Yellow/Red/White/Blue bags; BMW Rules 2016 |
| Q5D | Neurocysticercosis | T. solium eggs → brain cysts → seizures; "hole-with-dot" on CT; Albendazole + steroids |
This is a shared conversation. Sign in to Orris to start your own chat.